Related Experiment Video

Updated: Apr 25, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.2K

BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin

B T Paul1, Z Blanchard1, M Ridgway2

  • 1Cancer Institute and Department of Biochemistry, University of Mississippi Medical Center, Jackson, MS, USA.

Oncogene
|August 19, 2014
PubMed

Insights

BRCA1-IRIS protein promotes ovarian cancer metastasis and platinum resistance. Targeting BRCA1-IRIS with a novel peptide inhibits tumor growth and sensitizes cancers to chemotherapy, offering a new therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Ovarian cancer is a leading cause of gynecologic cancer mortality in the US.
  • Late diagnosis and platinum-resistant recurrences contribute to poor outcomes.
  • Identifying novel therapeutic targets is crucial for treating advanced ovarian cancers.

Purpose of the Study:

  • To investigate BRCA1-IRIS as a novel therapeutic target for ovarian cancer, including platinum-resistant forms.
  • To elucidate the role of BRCA1-IRIS in ovarian cancer metastasis and chemoresistance.

Main Methods:

  • Analysis of BRCA1-IRIS, survivin, and FOXO3a expression in ovarian cancer samples.
  • In vivo studies using mice to assess tumor formation and metastasis with BRCA1-IRIS manipulation.
  • Investigation of BRCA1-IRIS-activated signaling loops (BDNF/TrkB and NRG1/ErbB2).
  • Evaluation of a novel inhibitory peptide targeting BRCA1-IRIS in cell lines and a mouse xenograft model.

Main Results:

  • Overexpression of BRCA1-IRIS and survivin, with lack of nuclear FOXO3a, observed in over half of ovarian cancer samples.
  • BRCA1-IRIS overexpression promoted metastasis in mice; silencing BRCA1-IRIS inhibited tumor formation.
  • BRCA1-IRIS activates BDNF/TrkB and NRG1/ErbB2 signaling loops, contributing to anoikis resistance and metastasis.
  • A novel inhibitory peptide targeting BRCA1-IRIS reduced tumor growth and sensitized ovarian tumors to cisplatin in mice.

Conclusions:

  • BRCA1-IRIS plays a significant role in ovarian cancer progression, metastasis, and platinum resistance.
  • Targeting BRCA1-IRIS, or its downstream signaling pathways (BDNF/TrkB, NRG1/ErbB2), represents a promising therapeutic strategy for advanced ovarian cancers.
  • The novel inhibitory peptide demonstrates potential for treating ovarian cancer, including resistant forms.

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.3K
Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

8.8K

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
3.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K